Company profile for Ark Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a biopharmaceutical company focused on the discovery and development of therapeutics addressing unmet medical needs in respiratory and lung diseases. With a product portfolio covering full disease cycle and patient segmentations, our drug candidates address a spectrum of acute and chronic respiratory and lung diseases that currently lack effective treatments.Ark Biosciences is a biopharmaceutical company that is dedicat...
We are a biopharmaceutical company focused on the discovery and development of therapeutics addressing unmet medical needs in respiratory and lung diseases. With a product portfolio covering full disease cycle and patient segmentations, our drug candidates address a spectrum of acute and chronic respiratory and lung diseases that currently lack effective treatments.Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Building 25, Lane 388, Shengrong Road, Pudong, Shanghai 201203
Telephone
Telephone
+86 21 50681677
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/arkbio-initiates-phase-ii-clinical-trial-of-ak0610-a-preventive-monoclonal-antibody-for-respiratory-syncytial-virus-infection-302598172.html

PR NEWSWIRE
30 Oct 2025

https://www.prnewswire.com/news-releases/arkbios-ziresovir-included-into-pediatric-rsv-drug-priority-list-by-who-302505263.html

PR NEWSWIRE
15 Jul 2025

https://www.prnewswire.com/news-releases/arkbios-new-drug-application-for-adhd-therapeutic-azstarys-accepted-and-granted-priority-review-by-china-nmpa-302481819.html

PR NEWSWIRE
15 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty